Fig. 7: TTFT outcome disparities within GPCR, SMAD, and STP-regulation PFGs. | Blood Cancer Journal

Fig. 7: TTFT outcome disparities within GPCR, SMAD, and STP-regulation PFGs.

From: Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets

Fig. 7

Kaplan Meier plots of PFG clusters (A) and heatmaps of PFG protein members expression (B) TTFT Kaplan Meier Plots of ANXA1, TFRC, and SMAD2.p245 stratified by median (C). Low expression of ANXA1 and TFRC and high expression of SMAD2.p245 result in shorter TTFT. Kaplan Meier plots of the Accumulation of poor prognosis protein expression (ANXA1, SMAD2.p245, TFRC) (D). Groups represent the presence of 0–3 negative prognostic expression patterns (low ANXA1 or TFRC and high SMAD2.p245). The presence of two or more of these expression patterns results in shorter TTFT in all CLL (top), Rai stage 0 (middle), and Rai stage I (bottom) patients.

Back to article page